HF-030

Heart Failure (HF)

Asia 52 years old male China Total Cost: 781

Patient Condition

End-stage dilated cardiomyopathy, LVEF 15%, NYHA class IV, repeatedly hospitalized for cardiogenic shock, and relied on positive inotropic drugs for maintenance. Heart transplant waiting list, but the waiting time is expected to exceed 12 months due to donor shortage.

Treatment Timeline

PhaseDetailsDate
Assessment of end-stage heart failure
LVAD implantation
postoperative rehabilitation
long-term management

Treatment Outcome

beforeLVEF 15%, NYHA class IV, dependent on inotropic drugs, unable to complete the 6-minute walk
afterLVEF (assisted) effective cardiac output recovery, NYHA class II, free of positive inotropic drugs, 6-minute walking distance of 450m
highlightPatients with end-stage heart failure were successfully freed from positive inotropic drugs after LVAD implantation, and their quality of life was significantly improved